Literature DB >> 24579691

The beginning of personalized medicine in sepsis: small steps to a bright future.

E Christaki1, E J Giamarellos-Bourboulis.   

Abstract

There is a growing recognition that there is a need for a more personalized approach towards sepsis care. In most clinical trials investigating novel therapeutic interventions against sepsis, patients have been considered a rather homogeneous population. However, there is probably more individual variability between septic patients than previously considered. The pathophysiology of sepsis is a complex and dynamic process that originates from the host immune response to infection and varies according to the genetic predisposition, immune status and co-morbid conditions of the host, the type of pathogen and the site and extent of infection. Until now, efforts to stratify septic patients according to their immune profile were hampered by the lack of specific biomarkers. Recent advances in molecular medicine have made it possible to develop tools that will facilitate a faster and more precise diagnosis of infection. Individual variability between each patient's responses to infection can assist in tailoring therapeutic interventions to the individual's disease profile and monitoring treatment response. In this review, we describe those recent advances in genomics and theragnostics, which are slowly entering clinical practice and which will make possible a more personalized approach to each septic patient in the next decade.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genomics; individualized medicine; metabolomics; personalized medicine; sepsis; septic shock; single nucleotide polymorphism; transcriptomics

Mesh:

Substances:

Year:  2014        PMID: 24579691     DOI: 10.1111/cge.12368

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  27 in total

1.  Peritoneal wash contents used to predict mortality in a murine sepsis model.

Authors:  Joshua W Kuethe; Emily F Midura; Teresa C Rice; Charles C Caldwell
Journal:  J Surg Res       Date:  2015-04-25       Impact factor: 2.192

2.  Improved survival in critically ill patients: are large RCTs more useful than personalized medicine? We are not sure.

Authors:  Luciano Gattinoni; Tommaso Tonetti; Michael Quintel
Journal:  Intensive Care Med       Date:  2016-09-12       Impact factor: 17.440

3.  Global metabolomic analysis of a mammalian host infected with Bacillus anthracis.

Authors:  Chinh T Q Nguyen; Vivekananda Shetty; Anthony W Maresso
Journal:  Infect Immun       Date:  2015-10-05       Impact factor: 3.441

Review 4.  Could Biomarkers Direct Therapy for the Septic Patient?

Authors:  Clark R Sims; Trung C Nguyen; Philip R Mayeux
Journal:  J Pharmacol Exp Ther       Date:  2016-02-08       Impact factor: 4.030

5.  Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.

Authors:  Michael A Puskarich; Michael A Finkel; Alla Karnovsky; Alan E Jones; Julie Trexel; Brooke N Harris; Kathleen A Stringer
Journal:  Ann Am Thorac Soc       Date:  2015-01

Review 6.  The Collaborative Cross mouse model for dissecting genetic susceptibility to infectious diseases.

Authors:  Hanifa Abu Toamih Atamni; Aysar Nashef; Fuad A Iraqi
Journal:  Mamm Genome       Date:  2018-08-24       Impact factor: 2.957

7.  Fc Gamma Receptor IIA (CD32A) R131 Polymorphism as a Marker of Genetic Susceptibility to Sepsis.

Authors:  Jaqueline Beppler; Patrícia Koehler-Santos; Gabriela Pasqualim; Ursula Matte; Clarice Sampaio Alho; Fernando Suparregui Dias; Thayne Woycinck Kowalski; Irineu Tadeu Velasco; Renato C Monteiro; Fabiano Pinheiro da Silva
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

8.  Individualized significance of the -251 A/T single nucleotide polymorphism of interleukin-8 in severe infections.

Authors:  M D Georgitsi; V Vitoros; C Panou; I Tsangaris; E Aimoniotou; N K Gatselis; E Chasou; G Kouliatsis; K Leventogiannis; D Velissaris; E Belesiotou; O Dioritou-Aggaliadou; E Giannitsioti; M G Netea; E J Giamarellos-Bourboulis; G Giannikopoulos; Z Alexiou; N Voloudakis; A Koutsoukou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-14       Impact factor: 3.267

9.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29

10.  Orally administered anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel anti-inflammatory personalized therapeutic approach.

Authors:  Tawfik Khoury; Dory Rotnemer-Golinkin; Lidya Zolotarev; Yaron Ilan
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.